Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib

Leukemia. 2010 Jun;24(6):1223-7. doi: 10.1038/leu.2010.79. Epub 2010 May 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aniline Compounds / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Cell Proliferation / drug effects*
  • Drug Synergism
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Nitriles / therapeutic use*
  • Piperazines / therapeutic use*
  • Proto-Oncogene Proteins c-abl / antagonists & inhibitors
  • Pyrimidines / therapeutic use*
  • Quinolines / therapeutic use*
  • Tumor Cells, Cultured
  • src-Family Kinases / antagonists & inhibitors

Substances

  • Aniline Compounds
  • Antineoplastic Agents
  • Benzamides
  • Nitriles
  • Piperazines
  • Pyrimidines
  • Quinolines
  • bosutinib
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Proto-Oncogene Proteins c-abl
  • src-Family Kinases